NJ-ZYCUS
4.4.2024 17:01:26 CEST | Business Wire | Press release
Zycus, a global leader in cognitive procurement technology solutions, set another new milestone by announcing integration with Microsoft Azure OpenAI Service. This integration is a step towards an ongoing effort to build the world’s first generative AI powered S2P platform. This continuous engagement will harness the power of advanced AI to transform end to end source to pay processes, offering unprecedented efficiency, compliance, and ease of use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401357521/en/
Zycus launched world's first Generative AI powered S2P platform in collaboration with Microsoft (Graphic: Business Wire)
Zycus has already incorporated various Generative AI capabilities in the existing S2P Suite under the Merlin Assist offering. It is available both through an App published on Microsoft Teams and via Zycus web app.
“We are thrilled to partner with Microsoft. Many of our clients, global enterprises from across the world, have deployed Merlin Assist as part of our early access program and share very encouraging feedback on ease of use, compliance, and productivity. We are certain that sourcing & procurement will be fundamentally transformed in the months to come,” said Aatish Dedhia, Founder & CEO of Zycus.
Samik Roy, Executive Director, Corporate Medium and Small Businesses, Microsoft India said, “AI will transform the way individuals, teams and organizations work. Zycus has integrated Azure OpenAI to infuse AI into its S2P Platform. The quantitative impact is very encouraging. From personalized experiences to streamlined workflows, AI will start becoming the cornerstone of Zycus’ customers’ success.”
Some top use cases of Generative AI are enhancing the complete S2P process:
1. Efficiency and Time-Saving Innovations:
Harnessing the power of Azure OpenAI Service, Zycus can enhance the end-to-end procurement lifecycle, starting from swift recommendations of alternate suppliers to simplifying contract management with abstract language contract processing. Zycus has also built autoscore RFP capability that accelerates proposal evaluations. These innovations reduce manual efforts, saving valuable time and minimizing errors.
2. Enhanced Source Aggregation and Risk Assessment:
Zycus users are empowered with powerful source aggregation and tracking, combined with robust risk assessment. Azure OpenAI Service’s advanced algorithms process thousands of articles daily delivering a fourfold boost in article processing throughput. iRisk generates compliance-related questionnaires, easing the assessment process while offering strategic suggestions for mitigating identified risks. This approach streamlines compliance processes and delivers actionable strategies for enhanced predictive risk management.
3. Democratized Procurement via Microsoft Teams:
Zycus has seamlessly integrated its platform with Microsoft Teams to boost adoption. This integration makes procurement accessible to everyone. From policy adherence, extracting contract line items to comprehensive supplier response summaries and RFQ (Request For Quotation) questionnaire generation, all the features are built to continuously enhance user experience and get maximum ROI from the platform.
4. Precision-Driven AI Models for Informed Decisions:
The integration ensures more accurate, data-driven insights on alternative items, PR/PO summaries, and price trends, facilitating smarter purchasing choices procurement decisions, minimizing risks and optimizing outcomes.
“By combining the strengths of Azure OpenAI with Zycus’ native source to pay platform, we are setting a new standard in the industry. Our clients can now experience enhanced efficiency, risk management, and user engagement, driving procurement transformation at scale,” said Aatish Dedhia.
About Zycus
Zycus is a leading global provider of end-to-end Source to Pay solutions, pioneering in the space of cognitive procurement, powered by its advanced Merlin AI Suite. With a strong emphasis on transforming the procurement landscape, Zycus leverages Generative AI to offer innovative, AI-driven capabilities that streamline procurement processes, enhance decision-making, and foster strategic sourcing and supplier management.
To see the Microsoft and Zycus integrated platform in action, join us on April 9, 1 PM - 2:30 PM ET.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401357521/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom